A B S T R A C T The effect of the antigen-induced, immunoglobulin (Ig)E-dependent release of mediators from human lung tissue was analyzed for coincident changes in the tissue levels of cyclic nucleotides. Simultaneously with the appearance of mediators, lung cyclic guanosine 3',5'-monophosphate (GMP) increased from 0.9±0.2 to 12.63+±4.5 pmol/mg protein and cyclic AMP increased threefold from the initial levels of 5.1+1. 4 pmol/mg protein. The release of histamine and prostaglandin (PG)F2,,, as well as the associated increases in cyclic nucleotides, peaked within 10 min of anaphylaxis. Antagonists of histamine's H-1 receptor prevented anaphylaxis-associated increases in cyclic GMP, whereas H-2 antagonists prevented the cyclic AMP response. Neither of these antagonists influenced the pattern or quantity of histamine or slow-reacting substance of anaphylaxis release. Prevention of PGF2, synthesis with acetylsalicylic acid failed to influence histamine or slow-reacting substance of anaphylaxis release or the concomitant increases in cyclic nucleotides. Histamine, added exogenously, produced a prompt increase in the cyclic AMP and cyclic GMP levels of human lung. As was seen after anaphylaxis, H-1 anatagonists prevented the cyclic GMP response to histamine, whereas H-2 antagonists prevented the cyclic AMP response.
H-1 antagonists prevented 50% of the PGF, synthesis accompanying anaphylaxis; H-2 antagonists had no effect. Exogenous histamine induced PGF2, synthesis; this synthesis was prevented by H-1 but not H-2 antagonists, and was reproduced by 2-methylhistamine (H-1 agonist) but not by dimaprit (H-2 agonist). Arachidonic acid generation of PGFu. was not influenced by antihistamines. Therefore, histamine interactions with human lung result in the synthesis of both PGFw, and cyclic GMP i? response to H-1 stimulation, and of cyclic AMP through H-2 stimulation.
INTRODUCTION
The pathophysiologic events leading to allergic bronchial asthma involve an interaction between inhaled allergens and immunoglobulin (Ig)E molecules fixed to the surface of mast cells. The resultant secretion of granules from the mast cell generates a variety of biologically active compounds (1, 2) that induce the airways obstruction. The biochemical steps in mast cell secretion have been partially sequenced (3) and a modulating role of cyclic AMP and cyclic guanosine 3',5'-monophosphate (GMP)l defined (4, 5) . Cyclic nucleotides influence the release of secretory granules by affecting the degree of mast cell microtubule polymerization-depolymerization (6) .
Of the mediators of anaphylaxis, histamine and the prostaglandins are capable of altering the cyclic nucleotide content of guinea pig (7) (8) (9) , canine (10) , and human ( 11, 12) lung and therefore might conceivably influence their own release process. Indeed, it has been suggested that histamine secreted from human peripheral basophilic leukocytes might be capable of autoinhibition through stimulation of cyclic AMP increases (13) . Thus, it was of interest to investigate the cyclic nucleotide responses of human lung to the endogenous release of the mediators of anaphylaxis. Much as has been seen in the guinea pig (7-9), profound elevations of lung cyclic AMP and cyclic GMP accompanied mediator release. Histamine was responsible both for the cyclic nucleotide changes and for a portion of the prostaglandin synthesis that occurs with antigen challenge. Furthermore, the lung responses to histamine (either endogenous or exogenous) were found to be related to specific receptor interactions; stimulation of H-1 re- ' Abbreviations used in this paper: AA, arachidonic acid; ASA, acetylsalicylic acid; GMP, guanosine 3',5'-monophosphate; IR-PGF2, immunoreactive PGF2,,; RIA, radioimmunoassay; SRS-A, slow-reacting substance of anaphylaxis. (12) . Macroscopically normal areas of peripheral lung tissue were dissected free ofpleura, large bronchi (>3-5 mm), and blood vessels, fragmented into _200-mg (wet wt) replicates, and washed extensively with Tyrode's buffer. The replicates were incubated for 2 h at 370C in undiluted serum from a patient (F. P.) allergic to ragweed. The IgE-sensitized replicates were washed and placed in 3 ml of Tyrode's buffer at 37°C.
The experimental protocol generally employed consisted of: after an initial 10 min at 37°C, ragweed antigen E (0.5 ug/ml) was added to each sample to initiate mediator release. From 15 s to 60 min later, the lung fragments were transferred to 1 ml iced 10% perchloric acid or to 3 ml distilled water. The mediator-containing supernate was frozen in a dry ice:acetone bath and kept at -80°C until assayed for histamine, SRS-A, and prostaglandin content (usually within 24 h). In each triplicate group of samples, all three supernates were assayed for mediators, one replicate was employed for the determination of residual histamine, and two replicates were employed for cyclic nucleotide and protein content (14) . The effects of pharmacologic agents were studied by incubating lung samples with the agent for an appropriate period (see text) before antigen challenge. All pharmacologic manipulations were studied in parallel with nonmanipulated (control) sets of lung samples.
In experiments not involving anaphylaxis, the tissue replicates were incubated for the appropriate interval with the antagonist or inhibitor under study and challenged with a stimulant for an appropriate time period (see text). The supernates and fragments were handled as above.
Bioassay of histamine and SRS-A. Histamine and SRS-A were quantitated by bioassay on the isolated, atropinized guinea pig ileum as described (15) . Residual tissue histamine was extracted from the lung fragments into distilled H20 by heating at 100°C for 5 min. The presence of acetylsalicylic acid (ASA) or H-2 antagonists had no effects on the bioassay. In contrast, H-1 antagonists prevented histamine's ability to contract the guinea pig ileum but did not interfere with the SRS-A assay. Preliminary analysis revealed that supernates that contained SRS-A did not lose activity through at least 7 days when rapidly frozen (-150°C) and maintained at -70'C.
Microenzyme assay ofhistamine. Samples collected in the presence of H-1 antagonists were analyzed by the microenzyme assay as described (16) . Briefly, histamine is converted to [14C]methylhistamine by incubation with [methyl-14C]S-adenosyl methionine. The [14C]methylhistamine is extracted into chloroform after alkalinization and is quantitated by liquid scintillation counting. Recovery is calculated on the basis of 10 nCi [3H]histamine added to each sample at the outset. Neither of the H-1 antagonists employed in these experiments interfered with the enzyme assay ofhistamine. Multiple samples were quantitated by both bioassay and microenzyme assay. The results were equivalent (+ 10%) in all cases.
Net percent histamine released is determined by: (nanograms released -spontaneous release/nanograms released + residual) x 100. SRS-A is expressed as units released per gram lung tissue. 1 U of SRS-A causes a contraction of the guinea pig ileum equivalent in height to that induced by 5 ng/ml histamine. The average release of histamine was 16.7 +1.5% (n = 14) and SRS-A was 2,400±901 U/g (n = 16).
Radioimmunoassay (RIA) of PGF,. The prostaglandins were determined by RIA (17) 4°C; 10 min), the supemate was decanted into scintillation vials, 10 ml Aquasol was added, and the radioactivity was determined in an LS-350 (Beckman Instruments, Inc., Fullerton, Calif.). The sensitivity of this assay is 10 pg.
The specificity of antisera employed was investigated and the amount of prostaglandin required to inhibit 50% binding of antiserum plus tritiated antigen was determined (in pico- PGFw is indicated in each figure and represents that quantity present in supemates of control specimens maintained for the longest time period under the experimental conditions. The mean peak quantity of IR-PGF2, produced by anaphylaxis of human lung was 102.5±32 ng/g lung tissue or 410±+130 pg/mg protein (n = 14).
Preparation of human lung tissue for the determination of cyclic nucleotide levels. The cyclic AMP and cyclic GMP levels in human lung tissue were determined as described (12) . To the replicates in 10% perchloric acid, 3,000 cpm of [14C]cyclic AMP (0.1 pmol) and 3,000 cpm of [3H]cyclic GMP (0.033 pmol) were added as a recovery label. The fragments were homogenized for 30 s at 4,000 rpm (Polytron homogenator, Brinkmann Instruments, Inc., Westbury, N. Y.) and centrifuged at 400 g for 15 min. The precipitates were retained and digested in 2 ml 0.1 N NaOH for 48-72 h for protein determination (14) and the supemates were neutralized with 5 N KOH with phenol red as pH indicator. After centrifugation (200 g for 15 min), the supernate was applied to 1.5 x 0.7-cm columns of Ag-1X8, equilibrated in 0.1 N formic acid. The columns were washed with 10 ml distilled water followed by 10 ml 0.1 N formic acid, the cyclic AMP was eluted with 10 ml 1 N formic acid, and the cyclic GMP was eluted with 15 ml 4 N formic acid. The eluates were lyophilized and then resuspended in acetate buffer (1.0 ml, 50 mM, pH 4.0-cyclic AMP or 0.5 ml, 50 mM, pH 6.2-cyclic GMP). The cyclic AMP level was determined with the protein binding assay (19) and the cyclic GMP by RIA (20 
RESULTS
Relationship between mediator release and cyclic nucleotide levels. The time course of the immunologic release of histamine, SRS-A, and PGFw. from 16 individual experiments is shown in Fig. 1 (upper  panel) . Histamine was detected after 1 min (31+9% of maximal release, n = 11), reached 81+-9% (n = 9) of maximal release by 5 min, and 98+2.5% of maximal release at 45 min (n = 6). Thus, the bulk of histamine release is rapidly completed ( ditional slower release is evident thereafter. IR-PGF, levels were significantly increased 2 min after challenge (43+14% of maximal release, n = 5, P < 0.05), peaked between 4 and 15 min, and declined to <50% of maximum by 60 min. SRS-A was not detectable until 2 min after challenge, the quantity released achieved statistical significance at 4 min (29+5% of maximum, n = 5, P < 0.001), peaked at 45 min (96+±4% of maximum, n = 4), and declined thereafter. The cyclic nucleotide content of the lung fragments was simultaneously assessed (Fig. 1, lower panel) . ,'M; n = 2) were examined (Fig. 2) The H-2 antagonists cimetidine and metiamide were 1,500 next examined (Fig. 3) . When an incubation of 20 min with 50-,uM concentrations of these antagonists was 1,250°CYCLIC AMP employed, no significant alteration in either the pattern .---4 CYCLIC GMP (Fig. 3, upper panel) or the amount (Table I ) of mediator 1,000 release was noted. The cyclic GMP response to anaphylaxis was also unchanged, whereas the cyclic 750 AMP changes usually accompanying anaphylaxis were totally prevented (Fig. 3 , lower panel and Table II) . 500
Both metiamide and cimetidine were equally effective.
The effects of ASA (10 ,Lg/ml) (24, 25) cyclic nucleotide changes were examined (Fig. 4) . The
,,-±-.---i---pattern (Fig. 4 , upper panel) and the quantity (Table I) P < 0.001). The cyclic AMP concentrations also rose significantly within 30 s of anaphylaxis (2.5 times control levels, n = 5, P < 0.05) to a maximal increase of 3 to 4 times control levels between 2 and 10 min after anaphylaxis. The control levels for cyclic AMP were 5.1+1.4 pmol/mg protein (n = 12) and reached an average maximal increase of 22.44+3.06 pmol/mg protein (n = 7, P < 0.001) at 10 min after antigen challenge.
Histamine's actions can be separated into H-1 and H-2 responses (21) on the basis of selective receptor responses (22) . H-1 effects include smooth muscle contraction and vascular permeability, whereas H-2 effects include gastric acid secretion and uterine contraction (22, 23 ). Pyrilamine and diphenhydramine are H-1 antagonists while cimetidine and metiamide are H-2 accompanying anaphylaxis was significantly reduced by the incubation with ASA (Table I) . In actual amounts, base-line IR-PGF2, was 22.1+8.2 pg/mg protein aiid anaphylaxis induced an increase to 103.9±+28.7 (n = 5; P < 0.025). After 30 min in 10 ,ug/ml ASA, baseline IR-PGF2, levels were 21.0+6.5 pg/mg protein and anaphylaxis induced an increase to 31.5+6.3, (n = 5; P > 0.30) ( Table I ). The cyclic nucleotide pattern after anaphylaxis in the presence ofASA (Fig. 4, lower panel) was the same as matched control samples (Table II) . The kinetic analysis of cyclic nucleotides was not carried out beyond 30 min after antigen challenge.
Effects of histamine upon lung cyclic nucleotides. The time course of the cyclic nucleotide response to 50 ,uM histamine was analyzed (Fig. 5 ). Within 30 s after the introduction of histamine, both cyclic GMP and cyclic AMP were elevated; peak responses were appreciated at 1-5 min and the levels returned to base line by 30 min. The peak increase in cyclic GMP was 5.8 times control and cyclic AMP was 4.4 times control. The peak effect of histamine appeared at 1-2.5 min. Therefore, a dose response of histamine (3-100 uM) was examined 1.0 min after stimulation. Histamine caused a significant (P < 0.05) increase in both cyclic AMP (240+15%, n = 5) and cyclic GMP (142±10%, n = 5) at 30 ,uM or more. The effects of antihistamines upon histamine-induced increases in cyclic nucleotides was studied (Fig. 6) . The cyclic AMP increase produced by histamine was prevented by the H-2 antagonist cimetidine and the cyclic GMP increase was prevented by the H-1 antagonist pyrilamine.
Effects of histamine upon PGF20 generation. In addition to preventing the cyclic GMP increase secondary to anaphylaxis, H-1 antagonists were also found to reduce the quantity of prostaglandins synthesized (Table I) ranged from 26 to 73% inhibition, was seen with two distinct H-1 antagonists, and was statistically significant (P < 0.05). The H-2 antagonists cimetidine and metiamide were without effect ( Table I ). The capacity of exogenous histamine (1-100 ,uM) to induce PGF2, synthesis was examined. Significant quantities of PGF2 were generated by 10-100 ,uM histamine. The time course of PGF2, synthesis in response to 50,M histamine was determined (Fig. 7 ).
Significant amounts of PGF2, were induced 60 s after histamine stimulation, levels peaked at 15 min, and diminished thereafter. Incubation of the lung fragments with 50 ,uM cimetidine for 20 min failed to influence PGF2,, synthesis, whereas the H-1 antagonist pyrilamine (50 ,M) completely prevented histamineinduced PGF2, release.
Specific histamine agonists are available: 2-methylhistamine has 20% of the H-1 activity of histamine but only 2% of its H-2 activity (26) . Dimaprit, on the other hand, has 20% of the H-2 activity and 0.001% of the H-1 activity (27) . The capacity of these agonists (1-1,000 ,u M) to generate PGF2, was, therefore, studied. Although 2-methylhistamine (10 ,tM or higher) generated significant quantities of PGF2, dimaprit at no concentration caused increased PGF2, The effects of pyrilamine on PGF2, generation by added arachidonic acid (AA, 1 ,ug/ml) was studied to determine if the H-i antagonist might have a nonspecific inhibitory capacity (Fig. 8) molecule for prostaglandin formation, nonspecifically induces prostaglandin synthesis (28) . PGF2, was increased from 8.8 to 16 pg/mg protein by 1 ug/ml AA. The presence of neither pyrilamine nor cimetidine (both 50 ,uM) influenced the capacity of AA to generate increased PGF, synthesis. Histamine (50 ,M), like AA, increased PGF2, by 6 pg/mg protein and when combined with AA generated a greater than additive increase of 18 .5 pg/mg protein (P < 0.01). Cimetidine failed to influence this increased production, whereas pyrilamine prevented a portion ofthe increased synthesis equivalent to that produced by histamine alone.
DISCUSSION
The IgE-dependent, antigen-induced secretion of the mediators of anaphylaxis from human lung is accompanied by significant increases in cyclic AMP and cyclic GMP. These changes occur simultaneously with the appearance of mediators and are related to histamine release. The evidence that suggests the causal role of histamine includes: (a) the capacity of histamine-receptor antagonists to prevent anaphylaxis-associated cyclic nucleotide changes, (b) the capacity of exogenously added histamine to reproduce these findings, and (c) the observations (7) (8) (9) (10) that anaphylactically released histamine causes similar changes in guinea pig and dog lungs. While prostaglandins are capable of causing similar effects on the cyclic nucleotide levels of the human lung (11, 12) A similar observation has been reported in guinea pig lung (7) and these findings suggest that a portion of the cell types in lung respond to H-1 stimulation with increases in cyclic AMP.
The prostaglandin synthesis accompanying lung anaphylaxis has been considered a secondary event (2, 29 (33, 34) .
The effect of nonsteroidal anti-inflammatory agents (25) on the immunologic generation of PG has been studied in several species including man (12, 35, 36) . Agents such as ASA or indomethacin consistently suppress the synthesis of prostaglandins that accompany anaphylaxis. The effects of these agents on the release of the other mediators of anaphylaxis are less clear: the release of histamine has been reported as unaffected (12) , inhibited (37), or enhanced (36), whereas SRS-A release may be unaffected (12) , inhibited (28), or enhanced (35) . Rat mononuclear cells stimulated with ionophore A-23187 synthesize a slow-reacting substance-like material through a cyclo-oxygenase pathway (38) , whereas a rat basophilic tumor produces a similar material through a lipoxygenase pathway (39) . It seems likely that antigen-induced SRS-A from human lungs is derived independently of ASA-sensitive cyclo-oxygenase enzymes but that the relationship to lipoxygenase enzymes needs a close evaluation.
One might have predicted that the selective increases in cyclic AMP or cyclic GMP seen after lung anaphylaxis in the presence of antihistamines would have resulted in modulation of mediator release. Histamine may have a cyclic AMP-dependent (13), H-2-mediated (40) autoinhibitory capacity in regard to basophil leukocyte histamine release. This observation may, in part, be species specific, because histamine is capable of inhibition of SRS-A release from bovine lung (41) but fails to influence mediator release from the rat peritonium (42) . Histamine H-2 receptor antagonists augment reversed anaphylactic histamine release from monkey skin (41) but not from rat lung (43) . The apparent enhancement of histamine release by H-2 antagonists may partly be a result of reduced histamine breakdown (44) . In the present series of experiments, no alteration in either the pattern or the quantity of histamine or SRS-A release was appreciated after anaphylaxis in the presence of H-1 or H-2 antagonists. There are several possible explanations for this lack of effect: (a) the mast cell release reaction may be beyond the cyclic nucleotide-modulatable steps (3) before histamine-induced increases; (b) the mast cell may be experiencing simultaneous increases in cyclic AMP and cyclic GMP which negate each other; or (c) the lung mast cell may not be responsive to histamine.
Based upon these findings, mediator release in human lung might be expected to produce a profound generalized increase in the cyclic AMP and cyclic GMP concentrations of lung as well as inducing the bronchospasm, mucosal edema, and other events that contribute to asthma. It seems likely that individual variations exist in H-1 or H-2 responsiveness as has been observed in mice (45) . Indeed, asthmatic subjects appear to have impaired H-2 responses (46) . Therefore, antigen-induced mediator release in the lungs of an asthmatic subject might initiate a series of responses including a relatively selective increase in cyclic GMP levels. The pathologic consequences of such an alteration are not clear but conceivably might contribute to the asthmatic diathesis.
